CRVS · Corvus Pharmaceuticals, Inc. · Stock research

Current Thesis

The leg on offer is unchanged from the last update and so is its central problem: soquelitinib, an oral ITK inhibitor, carries a registrational Phase 3 in relapsed/refractory peripheral T-cell lymphoma, a ~200-patient Phase 2 in atopic dermatitis (SIERRA1), and two further studies — hidradenitis suppurativa and asthma — guided to start later in 2026. On 2026-08-06 the company placed the Phase 3 interim futility analysis in Q1 2027, structured so an independent data-monitoring committee decides only whether the trial continues with no efficacy or safety data released publicly; final PTCL data is targeted late 2027 and SIERRA1 topline Q3 2027. The only company-linked readout still on the 2026 board is cohort 1 of Angel Pharmaceuticals' China Phase 1b/2 AD study, guided "late this year" from a 49%-held affiliate that is not the registrational path.

What has changed since the last note is the tape, not the calendar. The reference close was $13.92 on 2026-08-07 with RSI(14) at 47.5; the 2026-08-21 close was $14.46 with RSI(14) at 62.4, still 43.3% under the $25.52 52-week high. The three-month price change now reads +14.7%, but that window opens on 2026-05-21 — after the 2026-05-14 selloff — so the figure measures recovery off the May trough near $10 rather than a round trip on the Phase 1 data. Sell-side did not follow the milestone push-out down: Oppenheimer reiterated $33 and Barclays maintained $28 on 2026-08-07, H.C. Wainwright maintained $27 on 2026-08-10, Mizuho reiterated $30 on 2026-08-11, and stockanalysis.com showed a $33.14 consensus across 8 analysts (range $27–$42) as of 2026-08-15 against a $14.46 last close.

The narrative is maturing. Dating it: the name is well known to the specialist biotech bid after the 2026-04-17 Goldman initiation and the 2026-05-14 Phase 1 readout, and it is still working — the June–August recovery has held and RSI has climbed 15 points since the print. But new attention is thin. One news item appeared in the 30 days before the Q2 update (a 2026-07-01 Benzinga options-screen item), the 2026-08-06 miss produced no re-acceleration, and the four post-print analyst actions were all reiterations rather than fresh initiations. Price is grinding higher on flow while the dated reasons to own it sit in 2027.

Bullish and bearish views on Corvus Pharmaceuticals, Inc.

The model's bull view on Corvus Pharmaceuticals, Inc. (CRVS), in brief: Phase 1 AD efficacy has a placebo comparator, restated 2026-08-06: 75% of patients on 200 mg BID reached EASI-75 at 8 weeks versus 20% on placebo, roughly a quarter reached EASI-90 and about a third reached clear or almost-clear skin (SID meeting presentation, restated in the Q2… The bear view: The registrational catalyst moved roughly a year and the replacement releases no data. Both cases follow in full.

Bull Case

• Phase 1 AD efficacy has a placebo comparator, restated 2026-08-06: 75% of patients on 200 mg BID reached EASI-75 at 8 weeks versus 20% on placebo, roughly a quarter reached EASI-90 and about a third reached clear or almost-clear skin (SID meeting presentation, restated in the Q2 update). Off-drug durability of 30–90 days with placebo-comparable adverse events was reported in the 2026-05-14 release.
• Funding is settled past both 2027 gates: cash, equivalents and marketable securities of $215.2M at 2026-06-30 against $56.8M at 2025-12-31, runway guided into Q2 2028 — beyond the Q1 2027 futility analysis and the Q3 2027 SIERRA1 topline.
• Four indications on one molecule: Phase 3 PTCL and SIERRA1 were both described as enrolling on track at the 2026-08-06 update, with hidradenitis suppurativa and asthma studies anticipated to initiate later in 2026. HS is the newest addition to the board and had no place in the spring frame.
• Regulatory scaffolding stands: FDA Orphan Drug Designation in T-cell lymphoma and Fast Track for R/R PTCL after at least two prior systemic lines (2026-08-06 update).
• Analyst targets were not cut into the push-out: four maintained or reiterated ratings between 2026-08-07 and 2026-08-11, lowest of them $27.

Bear Case

• The registrational catalyst moved roughly a year and the replacement releases no data. The Q1 2027 interim is a continue/stop decision by the DMC; a pass confirms only that the trial proceeds. There is no efficacy print until late 2027 on PTCL and Q3 2027 on AD.
• Nothing dated resolves inside the next 30 days. The next company event is the Q3 business update, historically early-to-mid November, and the only 2026 readout belongs to a China affiliate whose cash runway the company said on 2026-06-09 it has limited ability to estimate.
• Burn is stepping up while the milestones step out. Q2 2026 R&D was $16.0M versus $7.9M a year earlier, G&A $3.3M versus $2.4M, and the loss per diluted share was $(0.19) against $(0.10) in Q2 2025 and a $(0.17) consensus — with two more trials still to be initiated.
• The gap between $14.46 and a $33.14 consensus is the widest kind of unresolved disagreement, and a recovering tape with no near-term data event is the setting in which shelf capacity gets used.
• The 2026-05-14 precedent cuts against clean data-driven re-rating: shares fell about 28% on a release carrying the 75% EASI-75 figure. Positive data has already proven capable of producing a negative print in this name.

Setup & Price Structure

The 2026-08-21 close of $14.46 sits above the June–July shelf that held through the Q2 disappointment and below the July high area marked by the $15.67 close on 2026-07-10. RSI(14) at 62.4 is the highest reading cited in this coverage since the May drawdown; the move from 47.5 on 2026-08-07 came without a company release, so it is flow rather than news. Distance to the $25.52 52-week high is 43.3%.

Crowding and positioning observables, stated without a verdict: consensus price targets cluster at roughly 2.3x the last close ($33.14, 8 analysts, as of 2026-08-15), and every post-print action was a reiteration rather than a cut or an initiation; news volume was one item in the 30 days into the print; there is no earnings date inside the next 30 days to force positioning; and the news and filing record reviewed for this refresh shows no insider sales and no new registration statement since the 2026-08-06 update. That last item is an absence, and a new S-3 or 424B5 filed into a recovering tape would reverse it.

The structural question is whether the June–August recovery shelf holds through an empty autumn. A weekly close below $12.50 would break it and re-open the May trough area near $10.

Catalyst Calendar (next 30 days)

• Nothing dated falls between 2026-08-22 and 2026-09-21. No earnings date, no guided readout, no scheduled regulatory action.
• ~2026-11 (est.) — Q3 2026 business update and financial results. Tests whether Q1 2027 futility timing, early-2027 SIERRA1 enrollment completion and the "into Q2 2028" runway all survive the higher burn.
• ~2026-12 (est.) — Angel Pharmaceuticals China Phase 1b/2 AD cohort 1 results, guided "late this year"; the only clinical readout on the 2026 board.
• ~2027-Q1 (est.) — Phase 3 PTCL interim futility analysis (DMC continue/stop; no public data).
• ~2027-Q3 (est.) — SIERRA1 Phase 2 AD topline, percent change from baseline in EASI at Week 12 in ~200 moderate-to-severe patients.

Elapsed catalysts

• ~2026-Q4 (est.) — Initiation of the hidradenitis suppurativa and asthma studies, guided at the 2026-08-06 update to start later in 2026. (passed 20d ago)

What Would Change Our Mind

The structure that matters is the June–August recovery shelf built after the May trough. Losing it removes the only piece of evidence that the market is willing to carry the name through a data-free stretch: a weekly close below $12.50 breaks that shelf and re-opens the ~$10 area, and would be the observable that the empty calendar is being priced rather than looked through.

Two non-price conditions carry equal weight. First, the Angel cohort-1 AD readout guided "late this year" passing 2026 year-end without publication leaves zero clinical events until the Q1 2027 futility gate, which itself publishes nothing. Second, any restatement at the ~November Q3 update that moves the Q1 2027 futility date again, or that alters the "into Q2 2028" runway language, would mark a second slippage on the same program within two quarters.

On the other side, the case strengthens if the HS and asthma studies are confirmed as initiated on the 2026 guide and Angel's cohort 1 reproduces the EASI-75 range from the 2026-05-14 Phase 1 dataset in a controlled Chinese cohort — a data-based reason to hold a calendar seat into 2027 rather than a target-price one.

Correlation Notes

• Neither move maps to an index.
• As a pre-revenue micro-cap with no product sales line, price behaviour tracks small-cap biotech risk appetite and rate expectations more than any company financial. This is an inference from the structure of the balance sheet, not a measured beta.
• The AD leg is valued against the injectable IL-4Rα franchise economics that Dupixent set. A competing oral program printing randomized Week-12 EASI-75 at or above the 75% Phase 1 figure would compress SIERRA1's perceived ceiling before Corvus reads out in Q3 2027.
• The PTCL leg is benchmarked against the trial's own comparator arm — physician's choice of belinostat or pralatrexate — so PFS expectations move with that standard of care rather than with T-cell lymphoma sector news.
• The 49% Angel stake adds a China regulatory and funding component that is not diversifiable inside this name; the 2026-06-09 release flagged limited visibility into Angel's cash runway.